Recombinant human erythropoietin is administered to patients with end-stage chronic kidney disease for the treatment of anemia. However, there are different factors that generate resistance to this treatment. This paper seeks to evaluate the impact of a structured team approach for the management of anemia in erythropoietin-resistant hemodialysis patients.
No takes yet. Share an insight, caveat, or question.
López et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: